JP2023549126A - ペプチド製剤および使用方法 - Google Patents

ペプチド製剤および使用方法 Download PDF

Info

Publication number
JP2023549126A
JP2023549126A JP2023527357A JP2023527357A JP2023549126A JP 2023549126 A JP2023549126 A JP 2023549126A JP 2023527357 A JP2023527357 A JP 2023527357A JP 2023527357 A JP2023527357 A JP 2023527357A JP 2023549126 A JP2023549126 A JP 2023549126A
Authority
JP
Japan
Prior art keywords
composition
seq
administration
lipid
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023527357A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023549126A5 (https=
Inventor
ニール ケイ． クリシュナ
ケンジ クニオン
Original Assignee
レアルタ ライフ サイエンシズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レアルタ ライフ サイエンシズ インコーポレイテッド filed Critical レアルタ ライフ サイエンシズ インコーポレイテッド
Publication of JP2023549126A publication Critical patent/JP2023549126A/ja
Publication of JP2023549126A5 publication Critical patent/JP2023549126A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2023527357A 2020-11-09 2021-11-03 ペプチド製剤および使用方法 Pending JP2023549126A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063111367P 2020-11-09 2020-11-09
US63/111,367 2020-11-09
PCT/US2021/057802 WO2022098682A1 (en) 2020-11-09 2021-11-03 Peptide formulations and methods of use

Publications (2)

Publication Number Publication Date
JP2023549126A true JP2023549126A (ja) 2023-11-22
JP2023549126A5 JP2023549126A5 (https=) 2024-11-12

Family

ID=81457409

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023527357A Pending JP2023549126A (ja) 2020-11-09 2021-11-03 ペプチド製剤および使用方法

Country Status (10)

Country Link
US (1) US20230414506A1 (https=)
EP (1) EP4240392A4 (https=)
JP (1) JP2023549126A (https=)
KR (1) KR20230106643A (https=)
CN (1) CN116437938A (https=)
AU (1) AU2021376124A1 (https=)
CA (1) CA3194447A1 (https=)
IL (1) IL302567A (https=)
MX (1) MX2023005395A (https=)
WO (1) WO2022098682A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022094372A1 (en) * 2020-11-02 2022-05-05 Realta Life Sciences, Inc. Peptides and methods of use

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012527244A (ja) * 2009-05-20 2012-11-08 バイオマリン ファーマシューティカル インコーポレイテッド Ｃ型ナトリウム利尿ペプチドの変異体
JP2018524402A (ja) * 2015-06-26 2018-08-30 イースタン バージニア メディカル スクール 合成ペプチド化合物及び使用方法
WO2019139886A1 (en) * 2018-01-09 2019-07-18 Realta Holdings, Llc Pic1 inhibition of myeloperoxidase oxidative activity in an animal model
WO2020109526A2 (en) * 2018-11-30 2020-06-04 Opko Ireland Global Holdings, Ltd. Oxyntomodulin peptide analog formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008013955A2 (en) * 2006-07-27 2008-01-31 Nektar Therapeutics Sustained release formulations for pulmonary delivery
SG11201510732VA (en) * 2013-07-26 2016-01-28 Sanofi Sa Anti-tuberculosis stable pharmaceutical composition in a form of a dispersible tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation
WO2017093810A2 (en) * 2015-10-14 2017-06-08 Pharcon Inc. Composition for intraoral delivery of biologically active peptides and proteins
US12018054B2 (en) * 2017-04-13 2024-06-25 Valneva Austria Gmbh Multivalent OspA polypeptides and methods and uses relating thereto
WO2020243220A1 (en) * 2019-05-28 2020-12-03 Realta Holdings, Llc Pic1 peptide compositions and methods of use thereof for treatment of hypoxic ischemic encephalopathy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012527244A (ja) * 2009-05-20 2012-11-08 バイオマリン ファーマシューティカル インコーポレイテッド Ｃ型ナトリウム利尿ペプチドの変異体
JP2018524402A (ja) * 2015-06-26 2018-08-30 イースタン バージニア メディカル スクール 合成ペプチド化合物及び使用方法
WO2019139886A1 (en) * 2018-01-09 2019-07-18 Realta Holdings, Llc Pic1 inhibition of myeloperoxidase oxidative activity in an animal model
WO2020109526A2 (en) * 2018-11-30 2020-06-04 Opko Ireland Global Holdings, Ltd. Oxyntomodulin peptide analog formulations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HAIR, P. S. ET AL.: "Inhibition of complement activation, myeloperoxidase, NET formation and oxidant activity by PIC1 pep", PLOS ONE, vol. 14, no. 12, JPN6025041127, 2019, pages 0226875, ISSN: 0005701289 *

Also Published As

Publication number Publication date
KR20230106643A (ko) 2023-07-13
IL302567A (en) 2023-07-01
US20230414506A1 (en) 2023-12-28
AU2021376124A1 (en) 2023-06-29
MX2023005395A (es) 2023-05-19
CA3194447A1 (en) 2022-05-12
WO2022098682A1 (en) 2022-05-12
EP4240392A1 (en) 2023-09-13
EP4240392A4 (en) 2024-10-09
CN116437938A (zh) 2023-07-14

Similar Documents

Publication Publication Date Title
NO333073B1 (no) Cytotoksiske peptider modifisert med en eller flere ikke-genetiske, voluminose og/eller lipofile aminosyrer.
EP4595950A2 (en) Annexin a1 n-terminal peptide formulations and methods
JP2023549126A (ja) ペプチド製剤および使用方法
JP2026065064A (ja) ペプチドおよび使用方法
KR20230121823A (ko) Glp-1/glp-2 이중 효능제의 약학적 조성물
US20240209036A1 (en) Peptides and methods of use
JP7804672B2 (ja) ペプチドおよび使用方法
WO2022165016A1 (en) Conjugates with inhibitory receptor ligands to induce anergy in insulin-binding b cells
CN110139659B (zh) 用于治疗干燥综合征的肽
CN117396215A (zh) 肽和使用方法
KR20250118301A (ko) 안지오텐신전환효소 2(ace2)에 대한 결합능이 있는 신규한 펩타이드 및 이의 용도
JPH01230528A (ja) 結核症の治療改善剤
AU2008201749A1 (en) Treatment of Infections and Other Disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241101

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241101

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250924

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251006

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260403